• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Phathom Pharmaceuticals, Inc. - Common Stock (NQ:PHAT)

7.390 +0.380 (+5.42%)
Delayed Quote Updated: 11:44 AM EDT, Oct 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 186,108
Open 7.040
Bid (Size) 7.370 (1,400)
Ask (Size) 7.390 (300)
Prev. Close 7.010
Today's Range 6.960 - 7.390
52wk Range 6.520 - 18.31
Shares Outstanding 43,614,075
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Phathom Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide Business Update on Thursday, October 29, 2026
October 19, 2026
Management to host conference call on Thursday, October 29, 2026, at 8:00 am EDT 
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA® (vonoprazan) at ACG 2026
October 12, 2026
From Phathom Pharmaceuticals
Via GlobeNewswire

Performance

52-Week Range 59.6% below 52-week high
7.390
6.5252W Low 18.3152W High
1 Week 4.3% below 1-week high
6.781W Low 7.721W High

Phathom Pharmaceuticals, Inc. - Common Stock (PHAT) traded between $6.52 and $18.31 over the past 52 weeks and last traded at $7.39, 59.6% below its 52-week high. Over the past week it ranged between $6.78 and $7.72.

Past 12 Months
+5.6%
-0.8%
-30.6%
-45.1%
-53.0%
-47.3%
1W +$0.39
1M -$0.06
3M -$3.26
6M -$6.08
YTD -$8.32
1Y -$6.62

PHAT was -47.3% over the past year, -45.1% over six months, -53.0% year to date, +5.6% in the last week.

12 Months vs Market
PHAT
-47.3%
DIA
+12.2%
SPY
+14.7%
QQQ
+17.7%
IWM
+11.3%

Over the past 12 months PHAT returned -47.3% versus DIA (Dow) +12.2%, SPY (S&P 500) +14.7%, QQQ (Nasdaq 100) +17.7% and IWM (Russell 2000) +11.3%.

Volume & Liquidity 0.13× 3-mo avg
Today 186,108 3-mo avg 1.4M
1W
1.4M
1M
1.3M
3M
1.4M
6M
1.3M
YTD
1.3M
1Y
1.2M

PHAT most recently traded 186,108 shares against a 3-month average daily volume of 1.4M.

More News

Read More
News headline image
Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting
October 08, 2026
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD
September 29, 2026
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals (PHAT) Falls After Cutting 2026 Revenue Guidance Despite Q2 Beat ↗
July 30, 2026
Via Chartmill
Phathom Pharmaceuticals (NASDAQ:PHAT) Smashes Q1 Expectations, Nears Profitability Milestone ↗
April 30, 2026
Via Chartmill
News headline image
PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law
September 16, 2026
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
September 01, 2026
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
PHAT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Phathom Pharmaceuticals, Inc. (PHAT)
August 03, 2026
From Levi & Korsinsky, LLP
Via Business Wire
Phathom Pharmaceuticals (NASDAQ:PHAT) Q4 2025 Earnings: Revenue Beat and Narrowed Losses Signal Path to Profitability ↗
February 26, 2026
Via Chartmill
News headline image
Phathom Pharmaceuticals Q2 Earnings Call Highlights ↗
July 30, 2026
Via MarketBeat
Topics Earnings
News headline image
Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
July 30, 2026
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026
July 20, 2026
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
June 23, 2026
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
May 22, 2026
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting
May 20, 2026
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting
May 01, 2026
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom (PHAT) Q1 2026 Earnings Transcript ↗
April 30, 2026
Via The Motley Fool
News headline image
Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
April 30, 2026
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026
April 20, 2026
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
April 06, 2026
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom (PHAT) Q4 2025 Earnings Call Transcript ↗
February 27, 2026
Via The Motley Fool
Topics Earnings
News headline image
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
February 26, 2026
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
February 23, 2026
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026
February 17, 2026
From Phathom Pharmaceuticals
Via GlobeNewswire

Frequently Asked Questions

Is Phathom Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Phathom Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Phathom Pharmaceuticals, Inc. - Common Stock trade on?
Phathom Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Phathom Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Phathom Pharmaceuticals, Inc. - Common Stock is PHAT on the Nasdaq Stock Market
What is the current price of Phathom Pharmaceuticals, Inc. - Common Stock?
The current price of Phathom Pharmaceuticals, Inc. - Common Stock is 7.390
When was Phathom Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Phathom Pharmaceuticals, Inc. - Common Stock was at 10/20/26 11:44 AM ET
What is the market capitalization of Phathom Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Phathom Pharmaceuticals, Inc. - Common Stock is 322.31M
How many shares of Phathom Pharmaceuticals, Inc. - Common Stock are outstanding?
Phathom Pharmaceuticals, Inc. - Common Stock has 322M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap